Create a Free Account
or
Create a Free Account
or
| # | Filing Date | Period End Date | Type | Report Link |
|---|---|---|---|---|
| No Data found | ||||
| # | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
|---|
Cantor Fitzgerald analyst Josh Schimmer reiterates Alector (NASDAQ:ALEC) with a Overweight.
Cantor Fitzgerald analyst Josh Schimmer reiterates Alector (NASDAQ:ALEC) with a Overweight.
Alector (NASDAQ:ALEC) reported quarterly losses of $(0.40) per share which beat the analyst consensus estimate of $(0.52) by 23...
Cantor Fitzgerald analyst Pete Stavropoulos reiterates Alector (NASDAQ:ALEC) with a Overweight.
Alector, Inc. (NASDAQ:ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today announced the presentati...
Cantor Fitzgerald analyst Pete Stavropoulos reiterates Alector (NASDAQ:ALEC) with a Overweight.
HC Wainwright & Co. analyst Andrew Fein reiterates Alector (NASDAQ:ALEC) with a Buy and maintains $35 price target.
HC Wainwright & Co. analyst Andrew Fein maintains Alector (NASDAQ:ALEC) with a Buy and lowers the price target from $41 ...
